Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

4/25 “We-are-currently-communicating-with-FDA-about-Cellectra, and-we-are-working-hard-to-receive-FDA-Phase-3-concurrence in June.” By Inovio.

Following the announcement, Oppenheimer analyst Hartaj Singh reiterated a Buy and a price target of $35 on the stock. Singh said in a note to investors, “We spoke briefly with management regarding the press release put out earlier today. Inovio assured us that the government has no insight on the ongoing Phase 2/3 trial, which is randomized and blinded.”

“Recent data from INO-4800 against COVID-19 variants adds to our belief that INO’s vaccine is safe and effective; which it should demonstrate in the Phase 2 update of the trial, planned shortly. In a counterintuitive way, we think that this release by the US Government could give INO significant flexibility on issues of timing, deployment, intellectual property and profitability for INO-4800,” Singh added."